Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 9, 2020

Coronavirus outbreak likely to cause clinical trial delays: Poll

Clinical trials, which are conducted in laboratories and designated centres, require the presence of professionals and constant monitoring of the enrolled subjects.

Clinical trials, which are conducted in laboratories and designated centres, require the presence of professionals and constant monitoring of the enrolled subjects. Lock-downs and contagion fears have resulted in work from home or leave of absence for many amid heightened measures among healthcare workers.

The US FDA recommended switching to virtual patient visits than direct visits during the pandemic outbreak.

Verdict tried to find whether the coronavirus outbreak could cause delays in clinical trials, through a poll.

Run between 26 March and 02 April, the poll received 527 responses, the analysis of which revealed that clinical trial delays due to the outbreak are very likely, as polled by 52% of the respondents.

Delays are somewhat likely, according to 23% of the respondents, meaning that three-fourth of the poll respondents foresee clinical trial delays.

One-fourth of the respondents don’t expect the coronavirus outbreak to cause clinical trial delays at all, however.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Clinical trial delays

Pharmaceutical companies are announcing the postponement of new clinical trials amid the outbreak, while few have announced delays to existing trials. Lilly, for example, stated that the timeline for its ongoing studies on mirikizumab, an experimental gastrointestinal treatment, would be delayed.

Another company Bristol paused the launch of new clinical trials for three weeks due to the ongoing pandemic.

Subdued clinical trial activity would result in revenue loss to hospitals and academic centres, in addition to the delays adding up to the cost of the drug developers.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU